Renalytix Plc

DB:2O9 Stock Report

Market Cap: €30.9m

Renalytix Management

Management criteria checks 2/4

Renalytix's CEO is James McCullough, appointed in Mar 2018, has a tenure of 6.67 years. total yearly compensation is $780.11K, comprised of 65.3% salary and 34.7% bonuses, including company stock and options. directly owns 0.058% of the company’s shares, worth €17.91K. The average tenure of the management team and the board of directors is 3.6 years and 1.3 years respectively.

Key information

James McCullough

Chief executive officer

US$780.1k

Total compensation

CEO salary percentage65.3%
CEO tenure6.7yrs
CEO ownership0.06%
Management average tenure3.6yrs
Board average tenure1.3yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has James McCullough's remuneration changed compared to Renalytix's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

-US$28m

Jun 30 2024US$780kUS$510k

-US$33m

Mar 31 2024n/an/a

-US$37m

Dec 31 2023n/an/a

-US$42m

Sep 30 2023n/an/a

-US$44m

Jun 30 2023US$1mUS$601k

-US$46m

Mar 31 2023n/an/a

-US$40m

Dec 31 2022n/an/a

-US$42m

Sep 30 2022n/an/a

-US$47m

Jun 30 2022US$636kUS$601k

-US$45m

Mar 31 2022n/an/a

-US$50m

Dec 31 2021n/an/a

-US$44m

Sep 30 2021n/an/a

-US$38m

Jun 30 2021US$1mUS$586k

-US$35m

Mar 31 2021n/an/a

-US$28m

Dec 31 2020n/an/a

-US$20m

Sep 30 2020n/an/a

-US$16m

Jun 30 2020US$488kUS$470k

-US$10m

Mar 31 2020n/an/a

US$28m

Dec 31 2019n/an/a

-US$8m

Sep 30 2019n/an/a

-US$5m

Jun 30 2019US$216kUS$269k

-US$42m

Compensation vs Market: James's total compensation ($USD780.11K) is above average for companies of similar size in the German market ($USD471.55K).

Compensation vs Earnings: James's compensation has been consistent with company performance over the past year.

CEO

James McCullough (56 yo)

6.7yrs

Tenure

US$780,110

Compensation

Mr. James R. McCullough served as Independent Non-Executive Director of LungLife AI, Inc. from July 08, 2021 to October 24, 2024. Mr. McCullough is CEO of Renalytix Plc.and served as Chairman Mr. McCulloug...

Leadership Team

NamePositionTenureCompensationOwnership
James McCullough
Chief Executive Officer & Director6.7yrsUS$780.11k0.058%
€ 17.9k
Fergus Fleming
CTO & Executive Director6.7yrsUS$425.70k0.17%
€ 53.1k
Michael Donovan
Chief Medical Officer6.7yrsUS$380.01k0%
€ 0
Julian Baines
Executive Chairmanless than a yearUS$14.89kno data
Howard Doran
Presidentless than a yearno datano data
Joel Jung
Interim CFO & Principal Accounting Officerless than a yearno datano data
Salim Hamir
Company Secretaryno datano datano data

3.6yrs

Average Tenure

61.5yo

Average Age

Experienced Management: 2O9's management team is considered experienced (3.6 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
James McCullough
Chief Executive Officer & Directorno dataUS$780.11k0.058%
€ 17.9k
Fergus Fleming
CTO & Executive Director6.7yrsUS$425.70k0.17%
€ 53.1k
Julian Baines
Executive Chairmanless than a yearUS$14.89kno data
Erik Lium
Independent Non-Executive Director6yrsno datano data
Christopher Mills
Independent Non-Executive Director6.7yrsno data0%
€ 0
Stephen Brunton
Member of Clinical Advisory Board1.3yrsno datano data
Matthew Budoff
Member of Clinical Advisory Board1.3yrsno datano data
Ralph Defronzo
Member of Clinical Advisory Board1.3yrsno datano data
Barry Freedman
Member of Clinical Advisory Boardno datano datano data
Joseph Vassalotti
Member of Clinical Advisory Board5.3yrsno datano data
Catherine Coste
Independent Non-Executive Director1.4yrsUS$68.15k0%
€ 0
Holly Mattix-Kramer
Member of Clinical Advisory Board1.3yrsno datano data

1.3yrs

Average Tenure

57.5yo

Average Age

Experienced Board: 2O9's board of directors are not considered experienced ( 1.3 years average tenure), which suggests a new board.